Premium
SU‐E‐U‐02: In Vivo Study of Pulsed Focused Ultrasound Mediated Nanodroplet‐Encapsulated Chemo‐Therapeutic Agent for Treatment of Prostate Cancer
Author(s) -
Chen L,
Chen X,
Gupta R,
Cvetkovic D,
Wang B,
Ma C
Publication year - 2013
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.4815155
Subject(s) - docetaxel , prostate cancer , medicine , lncap , prostate , urology , cancer , ultrasound , in vivo , oncology , nuclear medicine , radiology , biology , microbiology and biotechnology
Purpose: We developed techniques for the formulation of docetaxel encapsulated nanodroplets, which respond to ultrasound. This study aims to investigate the improvement of prostate cancer treatment by a novel drug delivery technique combining pulsed high intensity focused ultrasound (pHIFU) exposures and docetaxel encapsulated nanodroplets under MR image guidance using prostate cancers grown orthotopically in nude mice. Methods: Human prostate cancer (LNCaP) cells were implanted orthotopically. Tumor growth was monitored using MRI. When the tumors reached a designated volume of 91 ± 21 mm3, tumor bearing mice were randomly divided into 5 groups (n=5). Group 1 animals were treated with an IV injection of docetaxel‐encapsulated nanodroplets (DTX+ND) + pFUS. Animals in Group 2 were treated with pFUS alone. Animals in Group 3 were injected (IV) with docetaxel‐encapsulated nanodroplets (DTX+ND) alone, Group 4 received free docetaxel and Group 5 was used as control. The mean diameter of the drug‐loaded nanodroplets was 220 ± 30nm.Ultrasound treatment parameters were 1MHz, 25W acoustic power, 10% duty cycle and 60 seconds for each sonication. After treatment, animals were allowed to survive for 4 weeks. Tumor volumes were measured on MRI. Results: Compared with the control group, significant tumor growth delay was observed in Group 1 with p=0.039 at 4 weeks after treatment. There was no significant tumor growth delay observed for Group 2 (p=0.477), Group 3 (p=0.209) and Group 4 (p=0.476). Conclusion: Our preliminary results showed a great potential for prostate cancer therapy using targeted docetaxel + nanodroplets, which could be activated by pHIFU. More animal studies are warranted to confirm the results and to further optimize the docetaxel + nanodroplets delivery and pHIFU parameters.